The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...

Zytiga is one of the most important growth products for J&J, with worldwide sales of the drug in the first half of the year growing more than 38 per cent to reach $464m. Link NICE says no to early ...

Software to make running your open source project a little bit easier.

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he ...